Goldman Sachs initiated coverage of Sandoz (SDZNY) with a Buy rating and CHF 74 price target The firm views Sandoz as a global leader in the generics and biosimilar industry. The analyst sees further share upside, saying the company well positioned to benefit from the biosimilar growth opportunity.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDZNY:
- Sandoz downgraded to Sector Perform from Outperform at RBC Capital
- Sandoz announces partnership agreement with Samsung Bioepis
- Sandoz Group Earnings Call Highlights Biosimilar-Fueled Surge
- Sandoz price target raised to CHF 62 from CHF 55 at Berenberg
- Sandoz downgraded to Hold from Buy at Deutsche Bank